Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multi
This study aims to establish a link between urinary Sphingosine 1-Phosphate (S1P) levels and detrusor activity in multiple sclerosis (MS) patients. MS often involves urological symptoms, primarily overactive bladder. The gold standard for evaluation and treatment monitoring is invasive urodynamic testing. Preliminary r
| Condition(s) | Multiple Sclerosis |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This study aims to establish a link between urinary Sphingosine 1-Phosphate (S1P) levels and detrusor activity in multiple sclerosis (MS) patients. MS often involves urological symptoms, primarily overactive bladder. The gold standard for evaluation and treatment monitoring is invasive urodynamic testing. Preliminary research at Toulouse University Hospital suggests urinary S1P levels may be a potential biomarker for detrusor activity in MS. This study aims to confirm this potential biomarker's utility. |
| Who can participate | Inclusion Criteria: * French residents enrolled in the social security system * Patients diagnosed with multiple sclerosis (according to McDonald 2017 criteria), whether receiving treatment or not * Patients scheduled for urodynamic assessment as part of their management Exclusion criteria: * Pregnant or lactating females * Patients under legal guardianship * Untreated urinary tract infection at the time of inclusion * Known anatomical subvesical obstruction Known pelvic floor disorder Urothelial carcinoma Interstitial cystitis Augmentation cystoplasty |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | University Hospital, Toulouse |
| Locations | Toulouse, France |
| Start date | 2023-12-04 |
| NCT ID | NCT06161376 |
| Official listing | https://clinicaltrials.gov/study/NCT06161376 |